Is tremelimumab/tremelimumab a targeted or immune drug?

Tremelimumab is an immune checkpoint inhibitor rather than a targeted drug in the traditional sense. Its main mechanism of action is to relieve the immunosuppressive state of T cells by inhibiting cytotoxic T lymphocyte antigen 4 (CTLA-4), thereby enhancing the body's own immune system's ability to recognize and kill cancer cells. CTLA-4 is a key immune checkpoint molecule that plays a negative regulatory role in the T cell activation process and can limit immune responses to prevent autoimmune diseases. However, tumor cells often use this mechanism to evade immune surveillance, making it difficult for the immune system to clear cancer cells.

The immunomodulatory effect of temsitumumab has shown potential in the treatment of a variety of malignant tumors, including advanced hepatocellular carcinoma, non-small cell lung cancer and some solid tumors. Unlike targeted drugs, which usually act directly on specific genes or proteins of tumor cells, such as EGFR or HER2, temsitumumab exerts its anti-tumor effects indirectly by regulating the immune system, which also explains its broad-spectrum application potential in a variety of tumor types.

In addition, temsitumumab shows unique advantages in combination therapy. Studies have shown that when used in combination with PD-1/PD-L1 inhibitors, the efficacy and remission rate can be improved to a certain extent. This combination strategy takes advantage of the synergistic effect of different immune checkpoints to enable T cells to recognize and eliminate cancer cells more effectively, providing a new treatment option for patients with advanced or drug-resistant tumors.

It should be noted that as an immune drug, temsitumumab may cause immune-related adverse reactions, including rash, liver function abnormalities, enteritis or thyroid dysfunction, etc. Therefore, in clinical use, doctors usually conduct strict screening and follow-up of patients to detect and deal with potential adverse reactions in a timely manner.

Reference: https://www.drugs.com/mtm/tremelimumab.html